Blog

First iVAC3L Case in Israel

On April 7th, 2010 the first iVAC3L case was car­ried out in Sheba Medical Center, Tel Aviv, Israel, by Dr. Yigal Cassif.

The patient was a 53yr old male who was suf­fer­ing from acute myocardi­tis with car­dio­genic shock after resus­ci­ta­tion with IABP and required emer­gency sup­port. Before implan­ta­tion of the iVAC3L he had an EF of 20%. Continue read­ing “First iVAC3L Case in Israel”

Prosensa ini­ti­ates clin­i­cal devel­op­ment of PRO044 in an open label phase I/II study – Prosensa’s sec­ond clin­i­cal can­di­date for treat­ment of Duchenne Muscular Dystrophy

Leiden, March 30, 2010 – Prosensa, the Dutch based bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on RNA mod­u­lat­ing ther­a­peu­tics announces the start of a phase I/II clin­i­cal study for PRO044 in patients with Duchenne Muscular Dystrophy.

The objec­tive of this open label, dose-esca­lat­ing study is to eval­u­ate the safe­ty and tol­er­a­bil­i­ty of the sys­temic deliv­ery of PRO044 in twelve Duchenne Muscular Dystrophy (DMD) patients receiv­ing week­ly sub­cu­ta­neous injec­tions for a peri­od of five weeks. The effect of PRO044 will be assessed at the RNA lev­el, to demon­strate spe­cif­ic exon 44 skip­ping, and at the pro­tein lev­el, to demon­strate nov­el dys­trophin expres­sion in mus­cle biop­sies. Continue read­ing “Prosensa ini­ti­ates clin­i­cal devel­op­ment of PRO044 in an open label phase I/II study – Prosensa’s sec­ond clin­i­cal can­di­date for treat­ment of Duchenne Muscular Dystrophy”

Prosensa strength­ens its man­age­ment team – Berndt Modig appoint­ed as Chief Financial Officer

Leiden, March 17, 2010 – Prosensa, the Dutch based bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on RNA mod­u­lat­ing ther­a­peu­tics, announces the appoint­ment of Berndt Modig as Chief Financial Officer (CFO). Continue read­ing “Prosensa strength­ens its man­age­ment team – Berndt Modig appoint­ed as Chief Financial Officer”

Brake through to decrease the wait­ing list of organ trans­plan­ta­tion

Dutch-based donor organ per­fu­sion devices companyOrgan Assist BV today announced the suc­cess­ful com­ple­tion of sec­ond round invest­ment led by Dutch investor MedSciences Capital BV from Amsterdam, The Netherlands. Also par­tic­i­pat­ing in this equi­ty invest­ment are De Friesland Zorgverzekeraar NV, Hanzepoort BV, NoordTechVenture BV, Kennisconversiefonds BV and G.J. Smidfonds BV, all from the Netherlands. The financ­ing will enable Organ Assist to bring its first prod­ucts to mar­ket and to fur­ther devel­op their extend­ed prod­uct line. Continue read­ing “Brake through to decrease the wait­ing list of organ trans­plan­ta­tion”

First iVAC 3L Case in Belgium

On February 3rd the first iVAC 3L case was car­ried out in Erasme ULB hos­pi­tal, Belgium, by Dr Frederic Vandeneynden.
The patient was a 65yr old female who had been trans­ferred to the ICU after bypass surgery and who had been unable to recov­er. Before implan­ta­tion of the iVAC 3L she had a CO of 2.9L/M, EF of 20% and her kid­neys were begin­ning to fail. Without the iVAC 3L it was pre­dict­ed that she would have died the same day. Continue read­ing “First iVAC 3L Case in Belgium”